Piramal Pharma Solutions Partners with Ajinomoto to Expand ADC Manufacturing Capabilities
Published: 08 May 2026
Author: Towards Healthcare
Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd, and Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical manufacturing services and platform technologies, have announced a strategic collaboration.
CEO, Piramal Global Pharma, Peter DeYoung, said We are excited to collaborate with Ajinomoto Bio-Pharma Services and enhance our ADC platform by offering manufacturing support for AJICAP-based products. With the implementation of these capabilities, we will accelerate innovation and expand access to this technology for our customers and their patients worldwide.
According to Towards Healthcare, the antibody contract manufacturing market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 20.4 billion in 2026 to approximately USD 46.94 billion by 2035, representing a compound annual growth rate (CAGR) of 9.7% from 2026 to 2035. Growth is driven by the increasing number of clinical trials for antibody-based therapies, which is driving the demand for specialised manufacturing capabilities. With technological advancement and Innovations in manufacturing processes, such as single-use technology, the efficiency and scalability of antibody drug conjugate manufacturing have improved.
About Ajinomoto's AJICAP
This technology significantly improves the flexibility of molecular design and the efficiency of development and manufacturing of ADCs and other next-generation biopharmaceuticals. It helps to improve product quality and streamline manufacturing processes compared to conventional technologies. By preserving the antibody’s original function while delivering the drug precisely, AJICAP enables the development of safer and more effective therapeutics.
The technology has shown promise in producing site-specific antibody conjugates without antibody engineering, and it has been used to achieve non-traditional ADC production, such as antibody–protein conjugates and antibody–oligonucleotide conjugates.
About Piramal Pharma Solutions
Piramal Pharma Solutions is part of Piramal Pharma Limited (PPL) and operates as a CDMO, offering end-to-end solutions across the drug life cycle. The company serves clients through a globally integrated network of facilities located in North America, Europe, and Asia. It operates 17 development and manufacturing facilities worldwide, enabling it to cater to a diverse clientele across more than 100 countries.
It is dedicated to delivering high-quality products and services, reflecting its commitment to patient well-being and community health. The company emphasises innovation and sustainability in its operations, striving to create a positive impact on the healthcare landscape.
A recent report by Towards Healthcare highlights that the antibody contract manufacturing market is witnessing growth fueled by the focus of companies on developing targeted therapies and the rising prevalence of chronic and infectious diseases, driven by the increasing demand for antibody therapies and the need for outsourcing production processes.